MCL1 and cancer: Also, additive antitumor activity has been observed with gemcitabine and ABT‐737 in various cancers, where their combined effect disrupts the interaction between USP9X and Mcl‐1, enhancing apoptosis and potentially overcoming inherent drug resistance.36